RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma

Activating mutations in KRAS occur in 32% of lung adenocarcinomas (LUAD). Despite leading to aggressive disease and resistance to therapy in preclinical studies, the KRAS mutation does not predict patient outcome or response to treatment, presumably due to additional events modulating RAS pathways....

Descripción completa

Detalles Bibliográficos
Autores principales: East, Philip, Kelly, Gavin P., Biswas, Dhruva, Marani, Michela, Hancock, David C., Creasy, Todd, Sachsenmeier, Kris, Swanton, Charles, Downward, Julian, de Carné Trécesson, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512813/
https://www.ncbi.nlm.nih.gov/pubmed/36163168
http://dx.doi.org/10.1038/s41467-022-33290-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512813/
https://www.ncbi.nlm.nih.gov/pubmed/36163168
http://dx.doi.org/10.1038/s41467-022-33290-0

Ejemplares similares